FFM
COGT icon

Fairmount Funds Management’s Cogent Biosciences COGT Stock Holding History

Fairmount Funds Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213M Hold
5,503,418
– – 14.08% 4
2026
Q1 		$212M Sell
5,503,418
-3,500,000
-39% -$129M 15.3% 3
2025
Q4 		$320M Hold
9,003,418
– – 24.34% 1
2025
Q3 		$129M Buy
9,003,418
+2,777,777
+45% +$32.9M 11.63% 2
2025
Q2 		$44.7M Hold
6,225,641
– – 5.79% 10
2025
Q1 		$37.3M Hold
6,225,641
– – 5.79% 9
2024
Q4 		$48.6M Hold
6,225,641
– – 4.83% 10
2024
Q3 		$67.2M Hold
6,225,641
– – 5.45% 10
2024
Q2 		$52.5M Buy
6,225,641
+1,500,000
+32% +$11.4M 5.93% 8
2024
Q1 		$31.8M Buy
4,725,641
+1,166,666
+33% +$7.21M 3.46% 10
2023
Q4 		$20.9M Hold
3,558,975
– – 2.21% 11
2023
Q3 		$34.7M Hold
3,558,975
– – 4.17% 8
2023
Q2 		$42.1M Buy
3,558,975
+800,000
+29% +$9.18M 5.94% 5
2023
Q1 		$29.8M Hold
2,758,975
– – 5.12% 7
2022
Q4 		$31.9M Hold
2,758,975
– – 5.06% 7
2022
Q3 		$41.2M Hold
2,758,975
– – 7.24% 2
2022
Q2 		$24.9M Buy
2,758,975
+1,200,000
+77% +$8.19M 5.7% 8
2022
Q1 		$11.7M Hold
1,558,975
– – 2.76% 15
2021
Q4 		$13.4M Hold
1,558,975
– – 4.41% 9
2021
Q3 		$13.1M Hold
1,558,975
– – 4.77% 9
2021
Q2 		$12.6M Hold
1,558,975
– – 5.2% 8
2021
Q1 		$13.7M Hold
1,558,975
– – 5.77% 9
2020
Q4 		$17.5M Sell
1,558,975
-1
-0% -$11 6.26% 9
2020
Q3 		$13.7M Buy
+1,558,976
New +$16.3M 5.81% 8

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fairmount Funds Management's COGT Position: Q2 2026 in Review

Fairmount Funds Management held its Cogent Biosciences (COGT) position steady in Q2 2026 at 5,503,418 shares worth $213M. The position accounts for 14.08% of the portfolio, ranked #4.

Fairmount Funds Management first reported a position in COGT in Q3 2020 and has held it in 24 quarters since. The position peaked at $320M in Q4 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Fairmount Funds Management held 5,503,418 shares of Cogent Biosciences worth $213M as of Q2 2026.
  • Fairmount Funds Management left its Cogent Biosciences share count unchanged in Q2 2026.
  • Cogent Biosciences made up 14.08% of Fairmount Funds Management's portfolio in Q2 2026, its #4 holding.
  • Fairmount Funds Management first reported a position in Cogent Biosciences in Q3 2020 and has held it in 24 quarters since.
  • Fairmount Funds Management's Cogent Biosciences position peaked at $320M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Fairmount Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.